Business Context and Reporting Period
Company: Grifols, S.A.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2013
Accounting Basis: International Financial Reporting Standards (IFRS)
Business Overview: Grifols is a vertically integrated global producer of plasma derivatives, diagnostics, and hospital products. The company operates four divisions: Bioscience (89.3% of revenue), Diagnostic, Hospital, and Raw Materials and Others. It is the world's third-largest producer of plasma derivative products and the largest producer of Alpha-1 Proteinase Inhibitor (A1PI). The company operates 150 FDA-licensed plasma collection centers in the U.S. and manufacturing facilities in the U.S., Spain, Mexico, Switzerland, and Australia.
Key Financial Metrics (Year Ended Dec 31, 2013)
| Metric | 2013 (€ millions) | 2012 (€ millions) | Change |
|---|---|---|---|
| Net Revenue | 2,741.7 | 2,620.9 | +4.6% (+7.4% constant currency) |
| Gross Profit | 1,417.9 | 1,329.6 | +6.6% |
| Gross Margin | 51.7% | 50.7% | +100 bps |
| Operating Profit | 736.1 | 660.1 | +11.5% |
| Net Profit (Consolidated) | 342.1 | 255.4 | +33.9% |
| Net Profit Attributable to Parent | 345.6 | 256.7 | +34.6% |
| Basic EPS | €1.01 | €0.75 | +34.7% |
| Operating Cash Flow | 592.0 | 507.1 | +16.7% |
| Cash and Cash Equivalents | 708.8 | 473.3 | +49.7% |
| Total Debt (Non-current + Current Financial Liab.) | 2,811.4 | 2,886.4 | -2.6% |
Note: All figures in thousands of euros unless otherwise noted. Debt figures exclude trade payables.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased by €120.8 million (4.6%). On a constant currency basis, growth was 7.4%, driven by increased sales volumes in the Bioscience division across all regions. The reported growth was negatively impacted by a €72.5 million unfavorable foreign exchange fluctuation (USD/EUR).
- Margin Expansion: Gross margin improved to 51.7% from 50.7% due to manufacturing cost optimization and increased yield per liter of plasma. Cost of sales as a percentage of revenue decreased to 48.3%.
- Profitability: Net profit attributable to the parent increased by 34.6% to €345.6 million. This was driven by higher operating results and a decrease in net finance costs (down 12.3% to €237.4 million) due to refinancing benefits and improved market conditions.
- Divisional Performance:
- Bioscience: Revenue up 5.3% (8.2% constant currency), driven by albumin and A1PI sales.
- Diagnostic: Revenue down 3.0% due to the termination of certain distribution agreements, partially offset by new analyzer sales.
- Hospital: Revenue stable (+1.3%), with international sales offsetting declines in Spain due to health sector austerity.
- Acquisitions: In 2013, the company acquired 60% of Progenika (€37.0 million), 35% of Aradigm ($25.7 million), and 21.3% of TiGenix (€12.4 million).
Guidance, Outlook, and Risks
Subsequent Events and Financing
Following the reporting period, Grifols concluded the acquisition of the Novartis Diagnostic Business for $1.675 billion (closed January 2014). To finance this, the company entered into new credit facilities and issued $1.0 billion of 5.25% Senior Notes due 2022. Pro forma for these transactions, indebtedness would have been approximately $5.4 billion.
Capital Expenditures
The company plans cumulative capital expenditures of approximately €450 million from 2014 through 2016 to expand manufacturing capacity (targeting 12.5 million liters/year by 2016) and improve plasma collection centers.
Key Risks and Contingencies
- Indebtedness: The company carries significant debt levels. Covenants restrict dividends, additional debt, and asset sales. Failure to generate sufficient cash flow could impair the ability to service debt.
- Plasma Supply: Revenue growth is dependent on access to U.S. source plasma. Supply constraints or increased costs could materially affect operations.
- Regulatory Environment: Strict FDA and EMA regulations govern manufacturing (cGMP). Non-compliance could lead to shutdowns or recalls. The 2010 U.S. Healthcare Reform Law impacts reimbursement rates and rebate obligations.
- Product Liability: Risks associated with plasma-derived products include potential transmission of pathogens and adverse reactions, leading to liability claims.
- Foreign Exchange: Approximately 72% of 2013 revenue was denominated in U.S. dollars, exposing the company to EUR/USD fluctuations.
Investor Verification Checklist
- Debt Covenants: Verify compliance with leverage ratios and dividend restrictions under the New Credit Facilities and Senior Notes indentures.
- Novartis Integration: Monitor the integration progress and financial impact of the Novartis Diagnostic Business acquisition closed in January 2014.
- Plasma Collection Metrics: Track liters of plasma collected and donor retention rates to assess raw material security.
- Reimbursement Rates: Monitor changes in U.S. Medicare/Medicaid reimbursement rates and rebate requirements under the 2010 Healthcare Reform Law.
- Capital Project Timelines: Verify the completion dates and regulatory approvals for the new fractionation facilities in Clayton, NC, and Parets, Spain.
- Receivables Aging: Review the aging of trade receivables, particularly in Southern Europe (Spain, Italy, Portugal), where payment delays are common.